

PRD 2023USPCT

REMARKS/ARGUMENTS

Consideration of the above-identified application in view of the following remarks is requested.

The claims pending and under consideration are claims 1-10 and 12-14, and 16-32. Claim 13 has been amended without prejudice. New Claims 23-32 have been added all of which depend from elected claim 13 of Group VII. Support for the new claims can be found in the original claims and throughout the specification e.g., a page 19, lines 15 to 35. It is respectfully submitted that no new matter has been added by virtue of the present amendment.

In the Office Action the Examiner required Restriction to one of the following groups under 35 USC § 121 and § 372:

Group I: Claims 1-10, and 12 (in part wherein R^1 and R^2 each independently represents hydrogen, $C_{1-4}alkyl$, NR^9R^{10} , $C_{1-4}alkoxy$, $Het^3-O-C_{1-4}alkyl$; Q is optionally substituted $C_{3-8}cycloalkyl$) are drawn to a compound or composition which contains at least one compound of formula I according to claim 1, a process of preparing the composition and a method to use the compound or composition.

Group II: Claims 1-10, 12, 18, 19, 20, and 21 (in part, wherein R^1 and R^2 each independently represents hydrogen, $C_{1-4}alkyl$, NR^9R^{10} , $C_{1-4}alkoxy$, $Het^3-O-C_{1-4}alkyl$; Q is optionally substituted Het^1) are drawn to a compound or composition which contains at least one compound of formula I according to claim 1, a process of preparing the composition and a method to use the compound or composition.

Group III: Claims 1-10, 12, 18, 19, 20, and 21 (in part, wherein R^1 and R^2 each independently represents hydrogen, $C_{1-4}alkyl$, NR^9R^{10} , $C_{1-4}alkoxy$, $Het^3-O-C_{1-4}alkyl$; Q is optionally substituted Ar^2) are drawn to a compound or composition which contains at least one compound of formula (I) according to claim 1, a process of preparing the composition and a method to use the compound or composition.

Group IV: Claims 1-10, and 12, (in part, wherein R^1 and R^2 taken together . . . ; Q is optionally substituted $C_{3-8}cycloalkyl$) are drawn to a compound or composition which contains at least one compound of formula I according to claim 1, a process of preparing the composition and a method to use the compound or composition.

PRD 2023USPCT

Group V: Claims 1-10, 12, 18, 19, 20, and 21 (in part, wherein R¹ and R² taken together . . . ; Q is optionally substituted Het¹) are drawn to a compound or composition which contains at least one compound of formula I according to claim 1, a process of preparing the composition and a method to use the compound or composition.

Group VI: Claims 1-10, 12, 18, 19, 20, and 21 (in part, wherein R¹ and R² taken together . . . ; Q is optionally substituted Ar²) are drawn to a compound or composition which contains at least one compound of formula I according to claim 1, a process of preparing the composition and a method to use the compound or composition.

Group VII: Claims 13, and 16 are drawn to a compound of formula (I') and a method of treating pathologies associated diseases using the compound of formula (I').

Group VIII: Claims 14 and 22 are drawn to a compound of formula (I'') and a method of use of the compound for treating pathologies associated diseases using the compound of formula (I'').

Group IX: Claim 17 is drawn to a method of preparing 1-hydroxy-4-aminoadamantane (formula (II-B)).

In response, Applicants hereby elect the subject matter of Group VII with traverse. Applicants respectfully traverse on the grounds that the examination of the entire application can be made without serious burden (MPEP 803).

Based on the foregoing, Applicants respectfully request that the Restriction Requirement be withdrawn.

Applicant respectfully request examination of the captioned application and allowance of same.

PRD 2023USPCT
Please charge any fees, which may be required for this submission to Johnson & Johnson
Deposit Account 10-0750/PRD2023USPCT/DK

Early favorable action on the merits is respectfully requested.

Respectfully submitted,

By /David Knasiak/
David Knasiak
Reg. No. 45,991

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-1287
Dated: August 28, 2006